ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 19, 2024
Walmart Executing Well, Raises Guidance
Image Source: Walmart. Looking ahead to all of fiscal 2025, Walmart now expects constant currency net sales to increase in the range of 4.8%-5.1% versus 3.75%-4.75% previously. Constant currency adjusted operating income is targeted in the range of 8.5%-9.25% growth in the year versus 6.5%-8% previously. Adjusted earnings per share is expected in the range of $2.42-$2.47 up from its prior forecast of $2.35-$2.43. Walmart continues to execute well in the current market environment, and we liked its raised guidance. The high end of our fair value estimate range stands at $90 per share.
Nov 19, 2024
Disney Sets Positive Long-Term Guidance
Image Source: Valuentum. Looking to guidance, Disney expects high-single digit adjusted earnings per share growth in fiscal 2025, roughly $15 billion in cash flow from operations and approximately $8 billion in capital spending, translating into $7 billion in traditional free cash flow. The entertainment giant expects dividend growth to track earnings expansion, while it plans to buy back $3 billion in stock repurchases during the year. For 2026, the company expects double-digit adjusted earnings per share growth and double-digit growth in cash provided by operations. For 2027, management expects double-digit adjusted earnings per share growth. The high end of our fair value estimate range for Disney stands at $120.
Nov 15, 2024
Cisco Raises Fiscal 2025 Guidance
Image: Cisco’s shares have been choppy the past couple years. Looking to fiscal 2025, Cisco Systems expects revenue in the range of $55.3-$56.3 billion, up from a prior view of $55-$56.2 billion, and non-GAAP earnings per share in the range of $3.60-$3.66, up from $3.52-$3.58 previously. We like Cisco’s progression to a subscription base business model, its opportunities in artificial intelligence, while its forward price-to-earnings ratio remains attractive at roughly 16x current fiscal year earnings. The high end of our fair value estimate range is $67 per share.
Nov 13, 2024
Home Depot Navigating Macroeconomic Uncertainty Well
Image: Home Depot’s shares are flirting with all-time highs. Looking to fiscal 2024 guidance, Home Depot expects total sales to increase 4% including SRS Distribution and the 53rd week, up from the prior forecast of 2.5%-3.5%. The 53rd week is expected to add $2.3 billion to total sales, while its SRS acquisition is expected to contribute roughly $6.4 billion in incremental sales. Comparable sales are expected to decline roughly 2.5% for the 52-week period compared to fiscal 2023 and down 3%-4% previously. Adjusted diluted earnings per share is expected to decline roughly 1% from $15.25 in fiscal 2023, including the 53rd week and better than prior expectations calling for a 1%-3% decline. Shares yield 2.2% at the time of this writing.
Nov 11, 2024
Ameresco’s Backlog Continues to Build
Image: Ameresco’s backlog of future business remains strong and growing. Looking to full year 2024 guidance, Ameresco expects revenue in the range of $1.7-$1.8 billion, up 27% at the midpoint of the range. Gross margin is targeted in the range of 16%-16.5%, while adjusted EBITDA is targeted to grow 35% at the midpoint of the range, to $210-$230 million. Non-GAAP earnings per share is targeted in the range of $1.15-$1.35. We continue to like Ameresco’s backlog build, as we continue to monitor its debt position and adjusted operating cash flow trends closely. The firm remains an idea in the ESG Newsletter portfolio.
Nov 8, 2024
Dividend Increases/Decreases for the Week of November 8
Let's take a look at firms raising/lowering their dividends this week.
Nov 7, 2024
Gilead Raises Revenue and Non-GAAP Diluted EPS Guidance
Image Source: Gilead. At the end of the quarter, Gilead had $5 billion in cash and marketable securities compared to $8.4 billion at the end of the year, the decline primarily due to its $3.9 billion acquisition of CymaBay Therapeutics. For the full year 2024, Gilead raised its guidance for product sales to the range of $27.8-$28.1 billion, up from $27.1-$27.5 billion previously. Non-GAAP diluted earnings per share is now targeted in the range of $4.25-$4.45, up from $3.60-$3.90 previously. We liked Gilead’s revenue growth in the quarter, as well as its raised financial outlook for 2024. The high end of our fair value estimate range stands at $111 per share.
Nov 7, 2024
Albemarle Pursues Efficiency in the Wake of Lower Lithium Prices
Image Source: Albemarle. Albemarle is working hard in the face of weak lithium pricing, and the firm is driving cost and productivity improvements across its business. The firm noted that it is reducing its workforce by 6%-7%, which will help the company cut costs in the range of $300-$400 million, and it plans to decrease its fiscal 2025 capital spending by roughly half versus fiscal 2024 ($1.7-$1.8 billion), to an expected range of $800-$900 million. Total liquidity was $3.4 billion at the end of the quarter, including $1.7 billion in cash equivalents, while total debt was $3.6 billion. We continue to include Albemarle in the ESG Newsletter portfolio.
Nov 6, 2024
Realty Income’s AFFO Covers Dividends Paid in Third Quarter
Image: Realty Income’s shares have seen better days. Realty Income reported mixed third quarter results November 4 with revenue exceeding the consensus forecast but funds from operations coming up short. Revenue advanced 28.1% in the quarter on a year-over-year basis, with same store rental revenue up modestly (0.2%). However, net income per share and FFO per share fell to $0.30 and $0.98, respectively, from $0.33 and $1.04 in the same period a year ago. Adjusted funds from operations (AFFO) came in at $1.05 per share in the period, up from $1.02 in last year’s quarter, and comfortably higher than dividends paid per share of $0.789 over the same time. Our fair value estimate for Realty Income stands at $61 per share.
Nov 6, 2024
Cash-Rich Vertex Pharma Raises 2024 Product Revenue Guidance
Image: Vertex Pharma’s shares have done quite well the past couple years. We continue to like Vertex’s established position in cystic fibrosis and its opportunity in gene-editing therapies as well as a new class of medicine for acute pain (VX-548) that’s without the limitations of opioids. The company’s pipeline is also progressing nicely with three additional programs advancing to Phase 3 – suzetrigine in painful diabetic peripheral neuropathy (DPN), povetacicept in immunoglobulin A nephropathy (IgAN), and VX-880 in Type 1 diabetes (T1D). The high end of our fair value estimate range for Vertex stands at $640 per share.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.